11:07 AM EDT, 10/10/2024 (MT Newswires) -- MediWound ( MDWD ) said Thursday it will start a phase II clinical study in 2025 evaluating EscharEx versus a collagenase ointment that's marketed as Santyl in the US and Iruxol in Europe to treat venous leg ulcers.

The study will enroll 45 patients in the US and Europe and will run concurrently with the company's phase III trial in venous leg ulcer patients.

MediWound ( MDWD ) said the study is designed to support the biologics license application for EscharEx.

The company's shares were up nearly 1% in recent trading.

Price: 16.65, Change: +0.15, Percent Change: +0.91